Rick Gonzalez, AbbVie CEO (Pablo Martinez Monsivais/AP Images)
January 17, 2024 12:35 PM EST
Pharma

Hu­mi­ra biosim­i­lar mar­ket re­mains stag­nant, with Ab­b­Vie los­ing on­ly 2% of mar­ket share, Sam­sung re­port shows

Zachary Brennan

Senior Editor

Ab­b­Vie is show­ing off to the world how it’s main­tain­ing most of the sales vol­ume for the Hu­mi­ra (adal­i­mum­ab) fran­chise in the US, los­ing just …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times